Certain Breast Cancer Subtypes May Derive a Greater Benefit With Ribociclib Combo vs Chemo
Patients with luminal B and HER2E breast cancer subtypes may have a greater PFS benefit with ribociclib plus endocrine therapy vs combination chemotherapy.
Related Articles
FDA Grants Fast Track Designation to IMM-1-104 in NRAS+ Advanced Melanoma
The FDA has granted fast track designation to IMM-1-104 for the treatment of advanced melanoma.
Optimizing Treatment Sequences Remains Key in CLL/SLL
Real-world data presented at the 2024 ASH Annual Meeting evaluated the efficacy of the most common treatment sequences in CLL/SLL.
Tafasitamab Plus Lenalidomide/Rituximab Improves PFS in Relapsed/Refractory Follicular Lymphoma
Tafasitamab plus lenalidomide and rituximab improved median PFS vs lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma.
China’s NMPA Grants Breakthrough Therapy Designation to Savolitinib Plus Osimertinib in EGFR+ NSCLC
Savolitinib plus osimertinib received breakthrough therapy designation in China for pretreated, locally advanced or metastatic EGFR-positive NSCLC with MET amplification.
Selinexor Plus Ruxolitinib Displays Activity in Ruxolitinib-Pretreated Myelofibrosis
Selinexor plus ruxolitinib showed activity in patients with myelofibrosis who were treated with ruxolitinib.
Unpacking Key Data From the 2024 ASH Annual Meeting: With Andre Goy, MD
Andre Goy, MD, discusses top hematologic oncology research from the 2024 ASH Annual Meeting.
FDA Approves Remestemcel-L for Pediatric Steroid-Refractory Acute Graft-vs-Host Disease
The FDA has approved remestemcel-L-rknd for pediatric steroid-refractory acute graft-vs-host disease.
Novel Anti-Estrogen Therapies Are Poised to Expand Treatment Options in Advanced ER+ Breast Cancer
Seth Wander, MD, PhD on novel anti-estrogen therapies that could expand treatment options in estrogen receptor–positive advanced breast cancer.
FDA Approves Ensartinib for Locally Advanced or Metastatic ALK+ NSCLC
The FDA has approved ensartinib for patients with ALK+ locally advanced or metastatic NSCLC who have not previously received an ALK inhibitor.
How Luspatercept Could Shake Up MDS Management—With Rory Shallis, MD
Dr Shallis discusses the ELEMENT-MDS trial in MDS and the potential of intervening with luspatercept before patients become RBC transfusion dependent.